Abstract:Objective To compare the efficacy and safety of etanercept injection 50 mg once weekly combined with methotrexate (MTX) therapy for patients with active rheumatoid arthritis.Methods This study consists of 2 parts：a 12-week double-blind treatment period (part A) followed by a 12-week open-label safety study period (part B).The randomization of treatments in double-blind treatment period was completed through the clinical operations randomization environment (CORE) system.During part A,the subjects were randomly assigned to the etanercept 50 mg or placebo group. The dosage regimen for etanercept was 50 mg administered subcutaneously once weekly while MTX was administered orally.All subjects who completed part A received 50 mg etanercept once weekly and MTX1 during the open-label treatment.The primary endpoint was ACR 20 response at week 12.Secondary endpoint variables included physician／patient global assessments of disease activities,duration of morning stiffness,pain visual analog scale (VAS),health assessment questi onnaire (HAQ),CRP level and tender and swollen joint counts .The results of safety between the two groups were compared.The primary endpoint and other secondary binary endpoints were analyzed using the Fisher’s exact test.For continuous endpoints.the change from baseline was analyzed with analysis of covariance. Results One hundred and fifty six subjects satisfied modified intent-to-treat (mITT) population were enrolled during part A,of which 77 subjects were in the etanercept+MTX group,and 79 subjects were in the placebo+MTX group respectively.A total of 149 subjects completed part A.As early as week 4.the ACR 20 response achieved 39％ (30,77) in the etanercept group,which was significantly higher than that of the placebo group [16％(13／79),P<0.001].At week 12,the ACR 20 respouse achieved 62％(48,77)in the etanercept group and 23％(18／79) in the placebo group (P<0.01).From week 4,other study endpoints including physician global assessment,patient global assessment,duration of morning stiffness,pain VAS,HAQ,CRP level,tender joint counts,swollen joint counts were also compared.The results showed that all above efficacy endpoints in the etanercept+MTX group were better than those of the placebo+MTX group(P<0.01).But there Was no significant difference in the total adverse eriects between the two groups.Conclusion Etanercept 50 mg once weekly + MTX treatment for 24 weeks is well tolerated.During the first 12-week treatment period,the etanercept group has shown a rapid efficacy onset and a significantly better therapeutic effect compared to that of the placebo group.

[A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Study of Etanercept in Treatment of Ankylosing Spondylitis].

Treatment of Ankylosing Spondylitis with Recombinant Hnman Tumor Necrosis Factor-Fc Fusion Protein (etanercept) : a Multicenter, Randomized, Double-Blind, Placebo-Con-trolled Trial

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis

A short-term study on half-value dose and decrement etanercept plus conventional therapy in active ankylosing spondylitis

Efficacy and Safety of Etanercept for Patients with Ankylosing Spondylitis:A Systematic Review

Efficacy and Safety of Adalimumab in Chinese Adults with Active Ankylosing Spondylitis: Results of a Randomised, Controlled Trial

Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial

The Current Status of Usage and Treatment Adherence of Etanercept in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

Efficacy and Safety of a Novel Recombinant Human Tumor Necrosis Factor-Α Receptor Ⅱ : Fc Fusion Protein in Chinese Patients with Active Ankylosing Spondylitis: Results of a Randomized, Double-Blind,multicenter Trial

A multi-center,double-blind,randomized,placebo-controlled study on the efficacy and safety of etanercept and methotrexate in the treatment of active rheumatoid arthritis

Clinical Efficacy of Etanercept for Treating Ankylosing Spondylitis in 60 Cases

Clinical Efficacy and Safety Evaluation of Etanercept and Infliximab in Treatment of Adolescent Ankylosing Spondylitis

Etanercept/celecoxib on Improving MRI Inflammation of Active Ankylosing Spondylitis: A Multicenter, Open-Label, Randomized Clinical Trial.

Efficacy and safety of ultrasound-guided local injections of etanercept into entheses of ankylosing spondylitis patients with refractory Achilles enthesitis.

Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study

Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Safety and Efficacy of Golimumab in Chinese Patients with Active Ankylosing Spondylitis: 1-Year Results of a Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase III Trial.

Effective Serum Level of Etanercept Biosimilar and Effect of Antidrug Antibodies on Drug Levels and Clinical Efficacy in Chinese Patients with Ankylosing Spondylitis.

Efficiency and Safety of Etanercept in Patients with Rheumatoid Arthritis: an Open-Label Controlled Trial

Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial